PMS-FLUTICASONE PROPIONATE/SALMETEROL DPI POWDER

国: カナダ

言語: 英語

ソース: Health Canada

有効成分:

FLUTICASONE PROPIONATE; SALMETEROL (SALMETEROL XINAFOATE)

から入手可能:

PHARMASCIENCE INC

ATCコード:

R03AK06

INN（国際名）:

SALMETEROL AND FLUTICASONE

投薬量:

500MCG; 50MCG

医薬品形態:

POWDER

構図:

FLUTICASONE PROPIONATE 500MCG; SALMETEROL (SALMETEROL XINAFOATE) 50MCG

投与経路:

INHALATION

パッケージ内のユニット:

15G/50G

処方タイプ:

Prescription

治療領域:

ADRENALS

製品概要:

Active ingredient group (AIG) number: 0238341003; AHFS:

認証ステータス:

APPROVED

承認日:

2019-12-10

製品の特徴

PR
PMS-FLUTICASONE PROPIONATE / SALMETEROL DPI
Fluticasone Propionate and Salmeterol Inhalation Powder USP
Pr
pms-FLUTICASONE PROPIONATE / SALMETEROL DPI _ _
100 mcg Fluticasone Propionate and 50 mcg Salmeterol (as the Xinafoate
salt)
Dry Powder Inhaler
Pr
pms-FLUTICASONE PROPIONATE / SALMETEROL DPI
250 mcg Fluticasone Propionate and 50 mcg Salmeterol (as the Xinafoate
salt)
Dry Powder Inhaler
Pr
pms-FLUTICASONE PROPIONATE / SALMETEROL DPI
500 mcg Fluticasone Propionate and 50 mcg Salmeterol (as the Xinafoate
salt)
Dry Powder Inhaler
CORTICOSTEROID AND BRONCHODILATOR FOR ORAL INHALATION
PHARMASCIENCE INC.
6111 Royalmount Ave., Suite 100
Montréal, Canada
H4P 2T4
www.pharmascience.com
DATE OF PREPARATION:
November 9, 2020
Submission Control No: 242762
_pms-FLUTICASONE PROPIONATE-SALMETEROL DPI Product Monograph _
_ _
_ _
_ Page 2 of 53_
_ _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
...................................................... 3
SUMMARY PRODUCT INFORMATION
.............................................................................
3
INDICATIONS AND CLINICAL
USE...................................................................................
3
CONTRAINDICATIONS
........................................................................................................
4
WARNINGS AND PRECAUTIONS
......................................................................................
4
ADVERSE REACTIONS
......................................................................................................
14
DRUG INTERACTIONS
.......................................................................................................
21
DOSAGE AND ADMINISTRATION
...................................................................................
23
OVERDOSAGE
.....................................................................................................................
25
ACTION AND CLINICAL PHARMACOLOGY
................................................................. 25
STORAGE AND STABILITY
..